PE20221455A1 - Composicion farmaceutica que comprende selexipag - Google Patents
Composicion farmaceutica que comprende selexipagInfo
- Publication number
- PE20221455A1 PE20221455A1 PE2022000625A PE2022000625A PE20221455A1 PE 20221455 A1 PE20221455 A1 PE 20221455A1 PE 2022000625 A PE2022000625 A PE 2022000625A PE 2022000625 A PE2022000625 A PE 2022000625A PE 20221455 A1 PE20221455 A1 PE 20221455A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- selexipag
- patients
- drug
- diphenylpyrazin
- Prior art date
Links
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003841 selexipag Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000006619 Cytochrome P-450 CYP2C8 Inhibitors Diseases 0.000 abstract 1
- 206010019663 Hepatic failure Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 230000008406 drug-drug interaction Effects 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 208000007903 liver failure Diseases 0.000 abstract 1
- 231100000835 liver failure Toxicity 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019078905 | 2019-10-23 | ||
| PCT/EP2020/079698 WO2021078835A1 (en) | 2019-10-23 | 2020-10-22 | Pharmaceutical composition comprising selexipag |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221455A1 true PE20221455A1 (es) | 2022-09-21 |
Family
ID=75620412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000625A PE20221455A1 (es) | 2019-10-23 | 2020-10-22 | Composicion farmaceutica que comprende selexipag |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220401441A1 (enExample) |
| EP (1) | EP4048235A1 (enExample) |
| JP (2) | JP7646646B2 (enExample) |
| KR (1) | KR20220087443A (enExample) |
| CN (1) | CN114555088A (enExample) |
| AU (1) | AU2020369912A1 (enExample) |
| BR (1) | BR112022007207A2 (enExample) |
| CA (1) | CA3154802A1 (enExample) |
| EC (1) | ECSP22040921A (enExample) |
| IL (1) | IL292354A (enExample) |
| JO (1) | JOP20220093A1 (enExample) |
| MX (1) | MX2022004882A (enExample) |
| PE (1) | PE20221455A1 (enExample) |
| PH (1) | PH12022550937A1 (enExample) |
| WO (1) | WO2021078835A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR2022005274A1 (tr) * | 2022-04-05 | 2023-10-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Seleksi̇pag'in bi̇r kati di̇spersi̇yonunu i̇çeren bi̇r fi̇lm kapli tablet |
| TR2022005277A2 (tr) * | 2022-04-05 | 2023-10-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Yaş granülasyon i̇le i̇şlenmi̇ş seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet |
| TR2022005273A2 (tr) * | 2022-04-05 | 2023-10-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet |
| TR2022020995A1 (tr) * | 2022-12-28 | 2024-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Seleksi̇pag i̇çeren bi̇r tablet formülasyonu |
| CN116392491A (zh) * | 2023-04-11 | 2023-07-07 | 广东省实验动物监测所 | 司来帕格的药物组合物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI316055B (enExample) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| EP2246336B1 (en) | 2008-02-28 | 2020-07-01 | Nippon Shinyaku Co., Ltd. | Fibrosis inhibitor |
| WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | 勃起不全治療剤 |
| SI2289518T1 (sl) | 2008-06-23 | 2017-02-28 | Nippon Shinyaku Co., Ltd. | Terapevtsko sredstvo za vnetno črevesno bolezen |
| WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
| HRP20151443T1 (hr) | 2008-06-23 | 2016-01-29 | Nippon Shinyaku Co., Ltd. | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala |
| SG176915A1 (en) | 2009-06-26 | 2012-01-30 | Nippon Shinyaku Co Ltd | Crystals |
| WO2011024874A1 (ja) | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| AU2012296953B2 (en) | 2011-08-12 | 2016-10-20 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| SG11201804320QA (en) * | 2015-12-02 | 2018-06-28 | Nippon Shinyaku Co Ltd | Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide |
| JOP20190204A1 (ar) * | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
| AR114399A1 (es) * | 2018-02-21 | 2020-09-02 | Nippon Shinyaku Co Ltd | Composición granular, método de producción para composición granular y método de mejora de la propiedad de disolución para composición granular |
| EP3965767A1 (en) * | 2019-05-06 | 2022-03-16 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
-
2020
- 2020-10-22 JP JP2022523448A patent/JP7646646B2/ja active Active
- 2020-10-22 KR KR1020227012736A patent/KR20220087443A/ko not_active Withdrawn
- 2020-10-22 CN CN202080071283.2A patent/CN114555088A/zh active Pending
- 2020-10-22 PE PE2022000625A patent/PE20221455A1/es unknown
- 2020-10-22 EP EP20792448.1A patent/EP4048235A1/en active Pending
- 2020-10-22 JO JOP/2022/0093A patent/JOP20220093A1/ar unknown
- 2020-10-22 AU AU2020369912A patent/AU2020369912A1/en not_active Abandoned
- 2020-10-22 CA CA3154802A patent/CA3154802A1/en active Pending
- 2020-10-22 BR BR112022007207A patent/BR112022007207A2/pt not_active IP Right Cessation
- 2020-10-22 US US17/770,155 patent/US20220401441A1/en not_active Abandoned
- 2020-10-22 MX MX2022004882A patent/MX2022004882A/es unknown
- 2020-10-22 IL IL292354A patent/IL292354A/en unknown
- 2020-10-22 WO PCT/EP2020/079698 patent/WO2021078835A1/en not_active Ceased
- 2020-10-22 PH PH1/2022/550937A patent/PH12022550937A1/en unknown
-
2022
- 2022-05-20 EC ECSENADI202240921A patent/ECSP22040921A/es unknown
-
2025
- 2025-03-04 JP JP2025033867A patent/JP2025074286A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021078835A1 (en) | 2021-04-29 |
| JP7646646B2 (ja) | 2025-03-17 |
| KR20220087443A (ko) | 2022-06-24 |
| MX2022004882A (es) | 2022-08-04 |
| IL292354A (en) | 2022-06-01 |
| JOP20220093A1 (ar) | 2023-01-30 |
| EP4048235A1 (en) | 2022-08-31 |
| US20220401441A1 (en) | 2022-12-22 |
| CN114555088A (zh) | 2022-05-27 |
| BR112022007207A2 (pt) | 2022-07-26 |
| CA3154802A1 (en) | 2021-04-29 |
| PH12022550937A1 (en) | 2023-06-14 |
| JP2025074286A (ja) | 2025-05-13 |
| ECSP22040921A (es) | 2022-06-30 |
| JP2022553313A (ja) | 2022-12-22 |
| AU2020369912A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| PE20121084A1 (es) | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 | |
| AR060536A1 (es) | Agonista del receptor de glucocorticoides y composiciones farmaceuticas | |
| ECSP17013617A (es) | combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| AR079930A2 (es) | Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv) | |
| CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
| CL2010001484A1 (es) | Uso de una composicion que contiene metilamida del acido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluoro-fenoxi]-piridin-2-carboxilico, sales, hidratos o solvatos del mismo, dispersados dentro de una matriz solida, sola o en combinacion con otras terapias para tratar trastornos hiperproliferativos. (sol.div. 2173-2005). | |
| ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
| CL2008001868A1 (es) | Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica | |
| CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
| ECSP22040921A (es) | Composición farmacéutica que comprende selexipag | |
| BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| DK1915150T3 (da) | Anvendelse af thienopyridinonderivater som AMPK-aktivatorer og farmaceutiske sammensætninger | |
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| BR112022004099A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx | |
| ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
| BR112023017126A2 (pt) | Uso do composto ativado por akr1c3 | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| MX378947B (es) | Composición farmacéutica estable para administración oral. | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| NI200600270A (es) | Una composición farmacéutica antimicobacteriana que comprende un farmaco antituberculosis | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| BRPI0614197B8 (pt) | composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição |